Sugi Predict

Sugi Predict / Compounds / SCHEMBL2597284

SCHEMBL2597284

SCHEMBL2597284

CC(C)CC(=O)N(n1c(=O)[nH]c2cc(C(F)(F)F)c(-n3ccnc3)cc2c1=O)S(C)(=O)=O

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.34
▸ GRIA1 P42261 3/20 0.33
▸ GRIA2 P42262 3/20 0.33
▸ GRIA3 P42263 3/20 0.33
▸ GRIA4 P48058 3/20 0.33
▸ CD38 P28907 1/20 0.33
▸ GRIK1 P39086 1/20 0.33
▸ GRIK2 Q13002 1/20 0.33
▸ GRIK3 Q13003 1/20 0.33
▸ GRIK4 Q16099 1/20 0.33
▸ GRIK5 Q16478 1/20 0.33
▸ AR P10275 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2597308 0.91 CA12 (0.46) CA12CA9GRIA1GRIA2GRIA3
SCHEMBL2597387 0.90 CA12 (0.45) CA12CA9GRIA1GRIA2GRIA3
SCHEMBL2597304 0.90 CA12 (0.56) CA12CA9GRIA1GRIA2GRIA3
SCHEMBL2597206 0.89 CA12 (0.46) CA12CA9ALDH1A1GRIA1GRIA2
SCHEMBL2597401 0.88 CA12 (0.48) CA12CA9ALDH1A1GRIA1GRIA2
SCHEMBL2597273 0.88 CA12 (0.43) CA12CA9ALDH1A1GRIA1GRIA2
SCHEMBL2597266 0.87 CA12 (0.42) CA12CA9ALDH1A1GRIA1GRIA2
SCHEMBL2597445 0.85 CA12 (0.41) CA12CA9ALDH1A1GRIA1GRIA2
SCHEMBL2597333 0.83 CA12 (0.43) CA12CA9GRIA1GRIA2GRIA3
SCHEMBL2597389 0.79 CA12 (0.58) CA12CA9GRIA1GRIA2GRIA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571865-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES Novartis AG (CH) 2013-03-27 — — EP claimed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US claimed
WO-2011144666-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG (CH) 2011-11-24 — — WO claimed
EP-2571865-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES Novartis AG (CH) 2013-03-27 — — EP disclosed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US disclosed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US disclosed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US disclosed
WO-2011144666-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG (CH) 2011-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES GRIK2, GRIK1, GRIK4 CA12 1465/4885CA9 2087/4885ALDH1A1 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.